Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Fish and Richardson
Healthtrust
Baxter
AstraZeneca
Merck

Generated: May 21, 2019

DrugPatentWatch Database Preview

TRINTELLIX Drug Profile

« Back to Dashboard

Which patents cover Trintellix, and what generic alternatives are available?

Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and two patent family members in forty-one countries.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

Drug patent expirations by year for TRINTELLIX
Generic Entry Opportunity Date for TRINTELLIX
Generic Entry Date for TRINTELLIX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for TRINTELLIX
1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine monohydrobromide
1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl}piperazine
1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine
1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine hydrobromide
1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE HYDROCHLRIDE
1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine
1-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]piperazine
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-hbr
1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine
1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine hydrobromide
1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine
1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine hydrobromide
2796AH
3O2K1S3WQV
4-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide
4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium bromide
4CH-016292
508233-74-7
7034AB
960203-27-4
A3926
AB0165485
AC-27648
AC-28325
AJ-86685
AKOS016008748
AKOS016340374
API0019472
AX8224799
BCP05996
BCP09588
BDBM50400902
Brintellix
Brintellix (TN)
C18H22N2S.BrH
CCG-229998
CHEBI:76015
CHEBI:76016
CHEMBL2104993
CHEMBL2107387
CHEMBL2204360
CS-1471
CS-1472
D10184
D10185
DA-42264
EBD3080710
EX-A2348
FT-0686961
FT-0696676
GG-0052
GTPL7351
HG-0011
HSDB 8250
HY-15414
HY-15414A
KB-81458
KB-81459
KS-0000062Y
Lu AA 21004 hydrobromide
Lu AA 21004 hydrobromide;Lu AA21004 hydrobromide
Lu AA 21004 pound>>LuAA21004 pound>> Lu-AA21004 pound>> Lu AA21004 pound>> AA21004
Lu AA 21004|||1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine
Lu AA 21004|||1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine hydrobromide
Lu AA21004
Lu AA21004 (HBr)
Lu-AA-21004
Lu-AA21004-(HBr)
MolPort-023-298-791
MolPort-023-298-793
PIP107
Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-
Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, hydrobromide (1:1)
Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-
s8021
SB16506
SB16507
SC-53652
SC-95551
SCHEMBL236115
SCHEMBL237653
ST2408515
STL483777
SW219360-1
TKS641KOAY
UNII-3O2K1S3WQV
UNII-TKS641KOAY
VNGRUFUIHGGOOM-UHFFFAOYSA-N
vortioxetina
VORTIOXETINE
Vortioxetine (hydrobromide)
Vortioxetine (Lu AA21004)
Vortioxetine (Lu AA21004) HBr
Vortioxetine (Lu AA21004) hydrobromide
Vortioxetine (USAN)
Vortioxetine [USAN:INN]
Vortioxetine HBr
Vortioxetine hydrobromide
Vortioxetine hydrobromide (JAN/USAN)
Vortioxetine hydrobromide [USAN]
vortioxetine monohydrobromide
Vortioxetine, Lu AA21004
vortioxetinum
W-5909
W-5911
YQNWZWMKLDQSAC-UHFFFAOYSA-N
ZINC34051848

US Patents and Regulatory Information for TRINTELLIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TRINTELLIX
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 5 mg, 10 mg, 15 mgand 20 mg ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for TRINTELLIX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1436271 PA2014013 Lithuania ➤ Try a Free Trial PRODUCT NAME: VORTIOXETINUM; REGISTRATION NO/DATE: EU/1/13/891 20131218
1436271 2014C/036 Belgium ➤ Try a Free Trial PRODUCT NAME: VORTIOXETINE; AUTHORISATION NUMBER AND DATE: EU/1/13/891 20131220
1436271 300652 Netherlands ➤ Try a Free Trial PRODUCT NAME: VORTIOXETINE OF EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT ERVAN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
1436271 92397 Luxembourg ➤ Try a Free Trial PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Teva
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.